With over 0.48 million Entera Bio Ltd (ENTX) shares trading Friday and a closing price of $1.09 on the day, the dollar volume was approximately $0.52 million. The shares have shown a positive half year performance of 28.60% and its price on 01/12/24 gained nearly 34.07%. Currently, there are 28.81M common shares owned by the public and among those 22.05M shares have been available to trade.
Insiders at the company have transacted a total of 6 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 6 of these insider trades were purchases, accounting for 155,904 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
Shares of Entera Bio Ltd (NASDAQ: ENTX) opened at $0.836, up $0.03 from a prior closing price of $0.81. The company’s stock has a 5-day price change of 61.16% and 58.02% over the past three months. ENTX shares are trading 81.67% year to date (YTD), with the 12-month market performance up to 15.96% higher. It has a 12-month low price of $0.52 and touched a high of $1.48 over the same period. ENTX has an average intraday trading volume of 55.52K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 60.05%, 59.24%, and 42.58% respectively.
Institutional ownership of Entera Bio Ltd (NASDAQ: ENTX) shares accounts for 8.95% of the company’s 28.81M shares outstanding.
It has a market capitalization of $31.40M and a beta (3y monthly) value of 1.52. The earnings-per-share (ttm) stands at -$0.34. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.15% over the week and 10.40% over the month.
Analysts forecast that Entera Bio Ltd (ENTX) will achieve an EPS of -$0.08 for the current quarter, -$0.12 for the next quarter and -$0.75 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.08 while analysts give the company a high EPS estimate of -$0.08. Comparatively, EPS for the current quarter was -$0.1 a year ago. Earnings per share for the fiscal year are expected to increase by 28.89%, and -134.38% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Entera Bio Ltd (ENTX) as a “Strong Buy” at a consensus score of 1.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ENTX, a number of firms have released research notes about the stock. Aegis Capital stated their Buy rating for the stock in a research note on March 22, 2021, with the firm’s price target at $12.
